COMPASSION-16 / AK104-303
A two-headed antibody that blocks two immune brakes at once extended survival in advanced cervical cancer regardless of PD-L1 status.
PFS HR 0.62 and OS HR 0.64 (Lancet 2024), with benefit in both PD-L1-positive and PD-L1-negative subgroups. NMPA approved the first-line combination in 2024 (second-line monotherapy since 2022). It was not approved outside China by 2026.
- The treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- The treated group had about 36 percent lower chance of the event at any given time (hazard ratio 0.64).
- The absolute difference, how many more people out of 100 were helped, is not reported here.
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Persistent, recurrent, or metastatic cervical cancer, first line (China): cadonilimab (PD-1×CTLA-4 bispecific) + platinum-paclitaxel ± bevacizumab vs placebo + chemotherapy ± bevacizumab. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PD-1); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
445 participants enrolled.
Pages like this
not linked directly; found by shared links- TrialKEYNOTE-826
Shares Cisplatin, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
- TrialBEATcc / ENGOT-Cx10 / GOG-3030
Shares Cisplatin, Bevacizumab, Paclitaxel / nab-paclitaxel, Cervical cancer.
- TrialKEYNOTE-B96 / ENGOT-ov65
Shares Bevacizumab, Paclitaxel / nab-paclitaxel, PD-1.
- TrialINTERLACE
Shares Cisplatin, Paclitaxel / nab-paclitaxel, Cervical cancer.
- CancerVulvar cancer
Shares Cisplatin, Bevacizumab, Paclitaxel / nab-paclitaxel, PD-1.
- ProductPenpulimab
- TrialCheckMate 648
- TrialCheckMate 9DW